Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

After receiving his degree in Journalism & Media Communications from CSU in 2019, Erik began building his career in online media, and found his dream job when he joined Game Rant as a staff writer.

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

New Torchlight Infinite season 'Overrealm' is out now, which means it's time for my regular reminder that XD's free-to-play ARPG is worth your time if you're looking for a little break from the genre ...

After a century of observations spanning the breadth of the cosmos and theoretical insights that push humanity's vision of the universe to its utmost limits, we can finally, confidently say that the ...

It would not be an overstatement to say that metal-organic frameworks (MOFs) have redefined what materials can do for society. These porous crystalline structures are built from metal ions coordinated ...